Analyst consensus rating
Kura Oncology Analyst Rating: Strong Buy
Direct answer
Kura Oncology's consensus rating is Strong Buy.
13 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $32.00.
Forecast evidence checked November 21, 2026.
Get free Kura Oncology email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $6.91
- Average price target
- $32.00
- High price target
- $76.00
- Low price target
- $15.00
- Low target gap
- +117.1%
- Target upside
- +363.1%
- High target gap
- +999.9%
- Target range width
- 882.8%
- Consensus rating
- Strong Buy
- Analysts
- 13
- Evidence date
- November 21, 2026
- Valid through
- November 28, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Kura Oncology?
Kura Oncology has a verified Strong Buy consensus. The same dataset has an average price target of $32.00.
How far are Kura Oncology's low and high targets from the recorded price?
The low target implies +117.1%, while the high target implies +999.9%.
How many analysts are included in Kura Oncology's consensus?
The verified consensus includes 13 analysts.
How is Kura Oncology's target upside or downside calculated?
The average target of $32.00 is divided by the recorded price of $6.91, then one is subtracted to produce +363.1%. This does not guarantee a future return.
When was Kura Oncology's analyst forecast verified?
The data was verified on 2026-11-21. The dataset is valid through 2026-11-28.